A comment on: A non-randomized clinical trial to determine the safety and efficacy of a novel sperm sex selection technique

The Ethics Committee of the American Society for Reproductive Medicine advises clinics to inform patients that the sex of resulting embryos may be known as part of embryo testing and to ask them whether they wish to receive this information [2]. For those who have the financial capacity to pay for a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:PloS one 2023-03, Vol.18 (3), p.e0282208
1. Verfasser: Pennings, Guido
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The Ethics Committee of the American Society for Reproductive Medicine advises clinics to inform patients that the sex of resulting embryos may be known as part of embryo testing and to ask them whether they wish to receive this information [2]. For those who have the financial capacity to pay for an IVF cycle with PGT-A, this risk is likely too high. [...]the argument that embryo selection is ethically contentious may be correct in the larger population but it is unlikely to be decisive for both fertility patients and fertility doctors. Continuation of this follow-up after the move to IUI is needed to obtain more certainty. [...]the authors also compared the aneuploidy rate of the embryos of the study and the control group and found no statistically significant difference. [...]there would only be fewer embryos wasted if the high efficacy of the method would allow fewer embryos to be created.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0282208